Altamira Therapeutics LTD. (CYTOF) — SEC Filings

Overview

Altamira Therapeutics LTD. (CYTOF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Aug 29, 2025: Altamira Therapeutics Ltd. filed a Form 6-K on August 29, 2025, reporting for the period ending June 30, 2025. The company, formerly known as Auris Medical Holding Ltd., is incorporated in Bermuda and operates in the pharmaceutical preparations sector. This filing is a report of a foreign private is

Sentiment Summary

Across 17 filings, the sentiment breakdown is: 1 bearish, 15 neutral, 1 mixed. The dominant filing sentiment for Altamira Therapeutics LTD. is neutral.

Filing Type Overview

Altamira Therapeutics LTD. (CYTOF) has filed 11 6-K, 2 20-F, 1 SC 13G, 2 20-F/A, 1 SC 13D/A with the SEC between Jan 2024 to Aug 2025.

Filings by Year

2025 · 2024

Recent Filings (17)

• Altamira Therapeutics Files 6-K Report — 6-K · Aug 29, 2025 Risk: low
  Altamira Therapeutics Ltd. filed a Form 6-K on August 29, 2025, reporting for the period ending June 30, 2025. The company, formerly known as Auris Medical Hold
• Altamira Therapeutics Holds Annual Shareholder Meeting — 6-K · Jun 11, 2025 Risk: low
  Altamira Therapeutics Ltd. held its Annual General Meeting of Shareholders on June 11, 2025. The filing does not specify the outcomes or resolutions from this m
• Altamira Therapeutics Files May 2025 6-K Report — 6-K · May 9, 2025 Risk: low
  Altamira Therapeutics Ltd. (formerly Auris Medical Holding Ltd.) filed a Form 6-K on May 9, 2025, reporting as a foreign private issuer. The company, incorporat
• Altamira Therapeutics Files 2024 Annual Report — 20-F · Apr 30, 2025 Risk: medium
  Altamira Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as Auris Medical Holdin
• Altamira Therapeutics Ltd. Files 6-K Report — 6-K · Mar 10, 2025 Risk: low
  Altamira Therapeutics Ltd. filed a Form 6-K on March 10, 2025, reporting its status as a foreign private issuer. The company, formerly known as Auris Medical Ho
• Altamira Therapeutics Files December 2024 6-K Report — 6-K · Dec 20, 2024 Risk: low
  Altamira Therapeutics Ltd. filed a Form 6-K on December 20, 2024, reporting for the month of December 2024. The company, formerly known as Auris Medical Holding
• SC 13G Filing — SC 13G · Nov 14, 2024
• Altamira Therapeutics Faces Nasdaq Delisting Risk — 6-K · Oct 4, 2024 Risk: medium
  Altamira Therapeutics Ltd. received a letter on September 30, 2024, from the Nasdaq Listing Qualifications department regarding its non-compliance with the mini
• Altamira Therapeutics Ltd. Files 6-K Report — 6-K · Sep 24, 2024 Risk: low
  Altamira Therapeutics Ltd. filed a Form 6-K on September 24, 2024, reporting for the period ending June 30, 2024. The company, formerly known as Auris Medical H
• Altamira Therapeutics Launches Public Offering — 6-K · Sep 19, 2024 Risk: medium
  On September 17, 2024, Altamira Therapeutics Ltd. initiated a best efforts public offering. The company, formerly known as Auris Medical Holding Ltd., is a phar
• Altamira Therapeutics Files 20-F/A Amendment — 20-F/A · Jul 1, 2024 Risk: low
  Altamira Therapeutics Ltd. filed an amendment (No. 2) to its Form 20-F for the fiscal year ended December 31, 2023. This filing provides updated information and
• Altamira Therapeutics Files May 2024 6-K Report — 6-K · May 16, 2024 Risk: low
  Altamira Therapeutics Ltd. filed a Form 6-K on May 16, 2024, reporting information for the month of May 2024. The company, formerly known as Auris Medical Holdi
• Altamira Therapeutics Ltd. Files Amendment to Annual Report — 20-F/A · Apr 22, 2024 Risk: low
  Altamira Therapeutics Ltd. (CYTOF) filed a Amended Foreign Annual Report (20-F/A) with the SEC on April 22, 2024. Altamira Therapeutics Ltd. filed an amendment
• Altamira Therapeutics Files Routine 6-K Report — 6-K · Apr 16, 2024 Risk: low
  Altamira Therapeutics Ltd. filed a Form 6-K on April 16, 2024, reporting as a foreign private issuer. The company, formerly known as Auris Medical Holding Ltd.,
• Altamira Therapeutics Ltd. Files Annual Report on Form 20-F — 20-F · Apr 10, 2024 Risk: low
  Altamira Therapeutics Ltd. (CYTOF) filed a Foreign Annual Report (20-F) with the SEC on April 10, 2024. Altamira Therapeutics Ltd. filed its annual report on Fo
• Meyer Amends Altamira Therapeutics Filing — SC 13D/A · Mar 13, 2024 Risk: medium
  Thomas Meyer filed Amendment No. 13 to Schedule 13D for Altamira Therapeutics Ltd. on March 13, 2024. This filing indicates a change in beneficial ownership, th
• Altamira Files Pro Forma Financials for Bentrio® Spin-Off — 6-K · Jan 19, 2024
  Altamira Therapeutics Ltd. (Altamira) filed a 6-K on January 19, 2024, to include unaudited pro forma financial information related to the partial spin-off of i

Risk Profile

Risk Assessment: Of CYTOF's 15 recent filings, 0 were flagged as high-risk, 4 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Thomas Meyer
• Michael J. Lerner
• Steven M. Skolnick

Industry Context

Altamira Therapeutics Ltd. operates within the pharmaceutical preparations industry.

Top Tags

foreign-private-issuer (7) · 6-K (3) · regulatory-filing (3) · reporting (3) · annual-report (2) · pharmaceuticals (2) · corporate-update (2) · sec-filing (2) · amendment (2) · Altamira Therapeutics (2)

Key Numbers

• Fiscal Year End: 2024 — The period covered by the annual report.
• Filing Date: 20250430 — The date the 20-F was submitted to the SEC.
• Minimum Bid Price: $1.00 — The minimum closing bid price required by Nasdaq for continued listing.
• Compliance Deadline: March 30, 2025 — The date by which Altamira Therapeutics must meet Nasdaq's minimum bid price requirement.
• Outstanding Common Shares: 1,477,785 — As of December 31, 2023
• SEC File Number: 001-36582 — Identifies the company's filing with the SEC
• Trading Symbol: CYTO — For common shares on Nasdaq

Related Companies

ALTA

Frequently Asked Questions